ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Inclusion criteria

• Subjects voluntarily participate in the study, provide written informed consent, demonstrate good compliance, and are cooperative with follow-up.
• Age ≥18 years at the time of signing informed consent, regardless of gender.
• Diagnosis of hepatocellular carcinoma confirmed by imaging (according to AASLD criteria), histology, or cytology.
• BCLC Stage B or C.
• At least one measurable lesion per RECIST 1.1.
• ECOG score of 0-1.
• Child-Pugh liver function class A or B.
• Life expectancy ≥ 3 months.
• Adequate hematological and organ function.

Exclusion criteria

• Patients with hepatocellular carcinoma who are candidates for surgical radical cure, or have undergone radical surgery without evaluable lesions, or have a history of or are planned for liver transplantation.
• Pregnant or breastfeeding women.
• Individuals with known allergy or intolerance to recombinant humanized PD-1/PD-L1 monoclonal antibody preparations.
• Received local-regional therapy within 4 weeks before the first dose of the study drug, including but not limited to surgery, radiotherapy, hepatic artery embolism, TACE, hepatic artery infusion, radiofrequency ablation, cryoablation, or percutaneous ethanol injection.
• History of other malignant tumors within 5 years prior to screening, except for hepatocellular carcinoma.
• Presence of unhealed severe wounds, active ulcers, or untreated fractures.
• Active autoimmune disease or history of autoimmune disorders.
• Significant history of gastrointestinal diseases.
• Significant history of cardiovascular or cerebrovascular diseases.